Home | List of Topics | Cancer | Leukemia
Hairy cell leukemia (HCL) is a rare cancer of the blood. It affects B cells, a type of white blood cell (lymphocyte).
HCL is caused by the abnormal growth of B cells. The cells can look "hairy" under the microscope because they have fine projections coming from their surface.
HCL can lead to low numbers of normal blood cells.
The cause of this disease is unknown. It affects men more often than women. The average age of onset is 55. Hairy cell leukemia is rare.
During a physical exam, the doctor may be able to feel a swollen spleen or liver. An abdominal CT scan may be done to confirm this swelling.
A complete blood count shows low levels of white and red blood cells, as well as platelets.
Blood tests and a bone marrow biopsy can detect hairy cells. A test called TRAP can confirm the cancer diagnosis.
People with this disease may not need treatment in the early stages. Some patients may need an occasional blood transfusion.
If treatment is needed because of very low blood counts, a variety of chemotherapy drugs can be used. A cancer drug called interferon is also used. In most cases, chemotherapy can relieve the symptoms of the disease (put the disease into remission) for many years.
Removing the spleen may improve blood counts, but is unlikely to cure the disease. Antibiotics can be used to treat infections. People with low blood counts will receive growth factors and possible transfusions.
Newer chemotherapy treatments have greatly improved the survival of patients with hairy cell leukemia. Most patients with hairy cell leukemia can expect to live 10 years or longer with the disease.
The low blood counts caused by hairy cell leukemia can lead to infections, fatigue, and excessive bleeding.
Call your health care provider if you have significant bleeding. Also call if you have signs of infection, such as a persistent fever, cough, or general ill feeling.
There is no known way to prevent this disease.
Review Date:4/27/2007
Reviewed By:Rita Nanda, M.D., Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL. Review provided byVeriMed Healthcare Network.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The Agency for Health Care Administration (Agency) and this website do not claim the information on, or referred to by, this site is error free. This site may include links to websites of other government agencies or private groups. Our Agency and this website do not control such sites and are not responsible for their content. Reference to or links to any other group, product, service, or information does not mean our Agency or this website approves of that group, product, service, or information.
Additionally, while health information provided through this website may be a valuable resource for the public, it is not designed to offer medical advice. Talk with your doctor about medical care questions you may have.